Mechanisms of Manganese Neurotoxicity

锰神经毒性机制

基本信息

  • 批准号:
    8318602
  • 负责人:
  • 金额:
    $ 32.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-08-05 至 2016-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chronic exposure to high concentrations of manganese (Mn) results in adverse neurological health effects commonly referred to as manganism. Manganese neurotoxicity is a significant toxicological problem resulting from the use of manganese as a gasoline additive, and in welding, metal industries, pesticide manufacturing, pharmaceutical preparations, infant food formulations, and battery production. Manganese predominantly accumulates in the basal ganglia structures and causes mitochondrial dysfunction, oxidative stress, and apoptosis. However, cellular and molecular mechanisms underlying manganese neurotoxicity are poorly understood. We have been studying mitochondrial-dependent apoptotic signaling in manganese neurotoxicity and found that protein kinase C-delta (PKCd), a member of the novel PKC isoform family, is persistently activated by caspase-3 to promote apoptosis during manganese exposure. While studying the apoptotic signaling pathway in cell culture models of manganese neurotoxicity, we also unexpectedly identified that PKCd is upregulated both in protein and mRNA levels during manganese treatment. Further analysis of the PKCd promoter revealed that two key transcription factors, NFkB and SP1, regulate PKCd gene expression. Thus, our competitive renewal proposal aims to systematically characterize this gene-environment interaction by studying novel molecular mechanisms underlying manganese-induced upregulation of the proapoptotic PKCd gene. We propose to complete the study by pursuing the following specific aims: i) To characterize upregulation of an oxidative stress-sensitive proapoptotic kinase PKCd in mouse primary neuronal cultures and animal models following manganese exposure, ii) To investigate molecular mechanisms of manganese-induced upregulation of PKCd by examining its transcriptional regulation of a PKCd promoter, and iii) To further define the functional role of NFkB and SP1-dependent PKCd upregulation in manganese-induced neuronal damage during chronic manganese exposure. Cellular, molecular, and neurochemical approaches in relevant cell cultures and animal models of manganese neurotoxicity will be used. We anticipate that the proposed study will provide comprehensive information about how environmental exposure to manganese can alter the expression of the key proapoptotic gene PKCd to augment manganese neurotoxicity, and this knowledge may advance the development of novel translational approaches for the treatment of manganese neurotoxicity.
描述(由申请人提供):长期接触高浓度的锰 (Mn) 会导致神经系统健康受到不良影响,通常称为锰中毒。锰神经毒性是由于使用锰作为汽油添加剂以及在焊接、金属工业、农药制造、药物制剂、婴儿食品配方和电池生产中使用而引起的一个重要毒理学问题。锰主要积聚在基底神经节结构中,导致线粒体功能障碍、氧化应激和细胞凋亡。然而,人们对锰神经毒性的细胞和分子机制知之甚少。我们一直在研究锰神经毒性中线粒体依赖性细胞凋亡信号传导,发现蛋白激酶 C-δ (PKCd)(新型 PKC 亚型家族的成员)在锰暴露期间持续被 caspase-3 激活以促进细胞凋亡。在研究锰神经毒性细胞培养模型中的凋亡信号通路时,我们还意外地发现,在锰处理过程中,PKCd 的蛋白质和 mRNA 水平均上调。对 PKCd 启动子的进一步分析表明,两个关键转录因子 NFkB 和 SP1 调节 PKCd 基因表达。因此,我们的竞争性更新提案旨在通过研究锰诱导的促凋亡 PKCd 基因上调的新分子机制来系统地表征这种基因与环境的相互作用。我们建议通过追求以下具体目标来完成这项研究:i) 表征小鼠原代神经元培养物和动物模型中锰暴露后氧化应激敏感促凋亡激酶 PKCd 的上调,ii) 研究锰诱导上调的分子机制通过检查 PKCd 启动子的转录调控,进一步确定 NFkB 和 SP1 依赖性 PKCd 上调的功能作用慢性锰暴露期间锰引起的神经元损伤。将在相关细胞培养物和锰神经毒性动物模型中使用细胞、分子和神经化学方法。我们预计,拟议的研究将提供有关锰环境暴露如何改变关键促凋亡基因 PKCd 的表达以增强锰神经毒性的全面信息,并且这些知识可能会促进治疗锰神经毒性的新型转化方法的开发。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anumantha Gounder Kanthasamy其他文献

Anumantha Gounder Kanthasamy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anumantha Gounder Kanthasamy', 18)}}的其他基金

Novel Reengineered Microbiome-based Biologic Therapy to Treat Cognitive and Behavioral Symptoms of Alzheimer's Disease and Related Dementias
基于微生物组的新型生物疗法可治疗阿尔茨海默病和相关痴呆症的认知和行为症状
  • 批准号:
    10527152
  • 财政年份:
    2022
  • 资助金额:
    $ 32.32万
  • 项目类别:
Novel Reengineered Microbiome-based Biologic Therapy to Treat Cognitive and Behavioral Symptoms of Alzheimer's Disease and Related Dementias
基于微生物组的新型生物疗法可治疗阿尔茨海默病和相关痴呆症的认知和行为症状
  • 批准号:
    10677787
  • 财政年份:
    2022
  • 资助金额:
    $ 32.32万
  • 项目类别:
Novel Re-engineered L DOPA Probiotic Therapy for Parkinson's Disease
新型重新设计的左旋多巴益生菌疗法治疗帕金森病
  • 批准号:
    10688149
  • 财政年份:
    2021
  • 资助金额:
    $ 32.32万
  • 项目类别:
Protein Aggregation and Inflammasome Signaling in Manganese Neurotoxicity.
锰神经毒性中的蛋白质聚集和炎症小体信号传导。
  • 批准号:
    10508354
  • 财政年份:
    2021
  • 资助金额:
    $ 32.32万
  • 项目类别:
Novel Re-engineered L DOPA probiotic therapy for Parkinsons Disease
新型重新设计的左旋多巴益生菌疗法治疗帕金森病
  • 批准号:
    10453379
  • 财政年份:
    2021
  • 资助金额:
    $ 32.32万
  • 项目类别:
Novel Re-engineered L DOPA Probiotic Therapy for Parkinson's Disease
新型重新设计的左旋多巴益生菌疗法治疗帕金森病
  • 批准号:
    10618744
  • 财政年份:
    2021
  • 资助金额:
    $ 32.32万
  • 项目类别:
Novel Re-engineered L DOPA probiotic therapy for Parkinsons Disease
新型重新设计的左旋多巴益生菌疗法治疗帕金森病
  • 批准号:
    10043372
  • 财政年份:
    2020
  • 资助金额:
    $ 32.32万
  • 项目类别:
Neuroinflammation and microglial Kv1.3 in Parkinsons disease
帕金森病中的神经炎症和小胶质细胞 Kv1.3
  • 批准号:
    10528896
  • 财政年份:
    2017
  • 资助金额:
    $ 32.32万
  • 项目类别:
Novel Mechanisms of Pesticide-Induced Neurotoxicity
农药引起的神经毒性的新机制
  • 批准号:
    9906057
  • 财政年份:
    2017
  • 资助金额:
    $ 32.32万
  • 项目类别:
Neuroinflammation and microglial Kv1.3 in Parkinsons disease
帕金森病中的神经炎症和小胶质细胞 Kv1.3
  • 批准号:
    9921502
  • 财政年份:
    2017
  • 资助金额:
    $ 32.32万
  • 项目类别:

相似国自然基金

减少编程错误:基于认证内核的全新的快捷依赖类型PiSigma高级编程语言开发
  • 批准号:
    61070023
  • 批准年份:
    2010
  • 资助金额:
    30.0 万元
  • 项目类别:
    面上项目

相似海外基金

Optimization of electromechanical monitoring of engineered heart tissues
工程心脏组织机电监测的优化
  • 批准号:
    10673513
  • 财政年份:
    2023
  • 资助金额:
    $ 32.32万
  • 项目类别:
Early life stress impacts molecular and network properties that bias the recruitment of pro-stress BLA circuits
早期生活压力会影响分子和网络特性,从而影响促压力 BLA 回路的募集
  • 批准号:
    10820820
  • 财政年份:
    2023
  • 资助金额:
    $ 32.32万
  • 项目类别:
Microneedle patch for the stabilization and dose-sparing delivery of rabies vaccine
用于稳定和节省剂量输送狂犬病疫苗的微针贴片
  • 批准号:
    10759732
  • 财政年份:
    2023
  • 资助金额:
    $ 32.32万
  • 项目类别:
PREVENTING ALZHEIMER’S DISEASE-LIKE BRAIN PATHOLOGY IN HIV INFECTION BY TARGETING CCR5
通过靶向 CCR5 预防 HIV 感染中的阿尔茨海默病样脑部病变
  • 批准号:
    10700624
  • 财政年份:
    2023
  • 资助金额:
    $ 32.32万
  • 项目类别:
Resources, Workforce Development, and Animal Models for the Rutgers RBL
罗格斯大学 RBL 的资源、劳动力发展和动物模型
  • 批准号:
    10793863
  • 财政年份:
    2023
  • 资助金额:
    $ 32.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了